PLAVIX Living Proof means proven efficacy and a well established safety profile
PLAVIX is the only prescription antiplatelet with proven efficacy and a well established safety profile in a broad range of patients.
Proven Effectiveness
8.7% Relative Risk Reduction (P=0.045) in Patients with recent myocardial infarction (MI), recent ischemic stroke, or established peripheral arterial disease (PAD) for up to 3 years1,3
- N=19,185
- PLAVIX 75 mg vs. aspirin 325 mg
- Combined end point: MI, ischemic stroke, or vascular death
- Event rate: 9.8% for PLAVIX vs. 10.6% for aspirin
Although the statistical significance favoring PLAVIX over aspirin was marginal (P=0.045) and represents the result of a single trial that has not been replicated, the comparator drug, aspirin, is itself effective (vs. placebo) in reducing CV events in patients with recent MI or stroke. Thus, the difference between PLAVIX and placebo, although not measured directly, is substantial.
Learn more about the CAPRIE Trial
Learn more about PLAVIX Safety and side effects
20% Relative Risk Reduction (P=0.00009) in ACS† patients with unstable angina (UA)/non-ST-segment elevation MI (NSTEMI) (onset ≤24 hours; with loading dose‡) for up to 1 year1,4
- N=12,562
- PLAVIX 75 mg + aspirin 75 to 325 mg vs. placebo + aspirin 75 to 325 mg
- Combined end point: MI, stroke, or CV death independent of standard CV therapies with or without percutaneous transluminal coronary angioplasty (PTCA) and/or coronary artery bypass graft (CABG)
- Event rate: 9.3% for PLAVIX + aspirin vs. 11.4% for placebo + aspirin
- In the co-primary combined end point of MI, stroke, CV death or refractory ischemia, the relative risk reduction (RRR) was 14% (16.5% vs. 18.8%; P=0.0005). Only first events after randomization were counted in the composite end point.
†ACS=acute coronary syndrome (UA [unstable angina], NSTEMI, STEMI)
‡Patients in the PLAVIX + aspirin arm were randomized to a 300 mg PLAVIX loading dose followed by 75 mg PLAVIX once daily
Learn more about the CURE Trial
Learn more about PLAVIX Safety and side effects
7% Relative Risk Reduction (P=0.029) in ACS patients with STEMI (onset ≤24 hours) up to 28 days1,6
- N=45,852
- PLAVIX 75 mg + aspirin 162 mg vs. placebo + aspirin 162 mg
- Primary end point: all-cause mortality up to 28 days or hospital discharge
- Event rate: 7.5% for PLAVIX + aspirin vs. 8.1% for placebo + aspirin
- PLAVIX with aspirin also significantly reduced the relative risk of the co-primary combined end point of death, reinfarction, or stroke by 9% vs. placebo with aspirin (9.2% vs. 10.1%; P=0.002). Only first relevant events during the scheduled treatment period were counted in the composite end point. Patients who underwent percutaneous coronary intervention (PCI) were excluded.
Learn more about the COMMIT Trial
Learn more about PLAVIX Safety and side effects
36% Odds Reduction (P<0.001) in ACS patients with STEMI (onset ≤12 hours; with loading dose‡) up to 8 days1,7
- N=3,491
- PLAVIX 75 mg + aspirin 75 to 162 mg vs. placebo + aspirin 75 to 162 mg
- Primary end point: composite of an occluded infarct-related artery on the predischarge angiography, or death or recurrent MI before angiography, discharge, or day 8, whichever came first
- Event rate: 15% for PLAVIX + aspirin vs. 21.7% for placebo + aspirin
- Most of the events were related to the surrogate end point of vessel patency. Patients were scheduled to undergo angiography 48 to 192 hours after the start of study medication.
‡Patients in the PLAVIX + aspirin arm were randomized to a 300 mg PLAVIX loading dose followed by 75 mg PLAVIX once daily
Learn more about the CLARITY Trial
Learn more about PLAVIX Safety and side effects